There may or may not be an end to what all human beings can do, but there is surely nothing we do better than growing on a consistent basis. This progressive approach, on our part, has already got the world to hit upon some huge milestones, with technology appearing as a major member of the stated group. The reason why technology enjoys such an esteemed stature among people is, by and large, predicated upon its skill-set, which ushered us towards a reality that nobody could have ever imagined otherwise. Nevertheless, if we look up close for a second, it will become clear how the whole runner was also very much inspired from the way we applied those skills across a real world environment. The latter component was, in fact, what gave the creation a spectrum-wide presence, and consequentially, kickstarted a tech revolution. Of course, this revolution then went on to scale up the human experience through some outright unique avenues, but even after achieving such a monumental feat, technology will somehow continue to produce the right goods. The same has grown increasingly evident over the recent past, and assuming one new healthcare-themed development shakes out just like we envision, it will only make that trend bigger and better moving forward.
BIOLASE, the global leader in dental lasers, has officially released a set of groundbreaking findings from a 12-month follow-up to a clinical trial performed at The McGuire Institute. Understood to be the first-of-its-kind study to compare BIOLASE’s REPAIR® Perio protocol with the traditional minimally invasive surgical technique (MIST), the findings revealed that BIOLASE’s Waterlase REPAIR® Perio protocol had similar and sustainable clinical outcomes, over the 12-month study, as compared to traditional MIST in treating intrabony defects. Next up, it discovered that patients who underwent BIOLASE’s Waterlase REPAIR® Perio laser treatment reported significantly better patient-reported outcomes (PROs) after six months. Making these outcomes even more significant was the fact there was less pain, reduced bleeding, and minimal discomfort in participants, thus indicating a patient-friendly approach to periodontal care. Of course, part of the reason why that is the case talks to the treatment’s stated minimally invasive nature, which ensures effective and more comfortable treatment for patients. Rounding up highlights was the prospect of faster recovery. You see, patients in the BIOLASE Waterlase group reported a quicker reduction in swelling and discomfort.
“This exciting study provides further strong evidence that our Waterlase laser and REPAIR® Perio protocol is a safe and effective alternative to surgical treatment for intrabony periodontal defects with lasting results,” said Dr. Russell Morrow, the Chief Dental Officer at BIOLASE. “The results ensure patients will not have to compromise on effectiveness, or comfort when choosing a less invasive approach.”
Founded way back in 1987, BIOLASE today stands at a place where its proprietary laser products cover approximately 259 patented and 24 patent-pending technologies, each one markedly designed to provide biologically and clinically superior performance with less pain and faster recovery times. The company is primarily focused on providing dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. BIOLASE’s excellence in what it does can also be understood by the fact that it had, until December 31, 2022, sold over 45,500 laser systems in over 80 countries around the world.
“The study provides a firm rationale for an alternative surgical approach in the treatment of intrabony periodontal defects and forges the path for future comparisons using regenerative therapies in conjunction with the REPAIR® Perio technique,” said Rick H. Heard, DDS, MS and Executive Director of Clinical Research and Operations at the McGuire Institute, a network of master clinicians trained and qualified to conduct high-level clinical research in a practice-based setting and located strategically throughout the United States. “It also supports superiority over a minimally invasive surgical technique with respect to patient reported outcomes.”
